MHRA publishes Quarter 2 results and forecast for 2026 to 2027
The Medicines and Healthcare products Regulatory Agency (MHRA) has added its Quarter 2 results to its quarterly Results and Forecast update for 2026 to 2027, together with a letter from Lawrence Tallon. The update was published on 12 November 2026.
The quarterly report gives performance information and projections across the 2026/27 year. It covers regulatory timelines and measures of organisational performance, and sets out the Agency's priorities for the next quarter.
What the update covers
- Performance information and projections across 2026/27
- Regulatory timelines and measures of organisational performance
- The Agency's priorities for the next quarter
The update builds on the MHRA Results and Forecast 2025/26; 2026/27. The Agency says it supports its commitment to greater transparency about its performance, impact and future priorities, and that it aims to deliver predictable, reliable performance for customers.
Performance data for the MHRA's key performance indicators, along with the expected timeline to complete specific regulatory functions, will continue to be reported monthly on the established MHRA Performance Data page.
For UK manufacturers and suppliers of medicines and medical devices that deal with the regulator, the quarterly report and the monthly data page are the places the Agency publishes its timelines and priorities.